ACCESS Newswire·Nov 9, 2026, 6:00 AM ET

DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides Under FDA Enforcement Discretion Policy

DataMeds AI, Inc. (NASDAQ:MEDS) announced that its Corexa Pharmacy subsidiary completed its first commercial sale of one of six FDA-recommended compounded peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax).
The sales were conducted in compliance with the U.S. HHS Enforcement Discretion Policy following the FDA Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026.
The Six Peptides are not FDA-approved & have not been evaluated by the FDA for safety or efficacy.
Interim Co-CEO Gerald Commissiong confirmed the company can dispense these peptides in compliance with recent guidelines & intends to actively market the offering in the near future.
The company is currently finalizing a pricing model & will focus marketing efforts on prescribing physicians to ensure appropriate oversight for one-to-one patient prescriptions.
The U.S. compounding pharmacy market is projected to grow from $18.02 billion in 2025 to over $31.77 billion by 2034.
DataMeds AI integrates its EinsteinRx AI platform & PharmacyChain blockchain platform into the Health Lives Here mobile application & owns the Helomics Corporation diagnostics laboratory.
Corexa Health distributes select Tollo Health medical foods & dietary supplements under a wholesale arrangement.
The press release includes standard forward-looking statements regarding regulatory compliance, market acceptance, pricing, & potential risks associated with the new peptide offerings.